OncoMatch/Clinical Trials/NCT07665190
Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
Is NCT07665190 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Becotatug Vedotin and Pucotenlimab for hypopharyngeal squamous cell carcinoma.
Treatment: Becotatug Vedotin and Pucotenlimab — This clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-ADC) in combination with Pucotenlimab(Anti-PD-1 Monoclonal Antibody) as neoadjuvant therapy for patients with Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma. The primary objective is the pathological complete response(pCR)rate following neoadjuvant therapy. The secondary objective includes the major pathological response(MPR)rate following neoadjuvant therapy, the objective response rate (ORR), Organ preservation rate, Surgery postponement rate, event-free survival (EFS), overall survival(OS), and safety.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: concurrent anti-tumor therapies
Requirement for concurrent treatment with other anti-tumor therapies
Lab requirements
Blood counts
adequate organ function as defined by laboratory parameters
Kidney function
adequate organ function as defined by laboratory parameters
Liver function
adequate organ function as defined by laboratory parameters
Have adequate organ function as defined by laboratory parameters
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07665190 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages